RSI at 29.51 represents persistent one-directional selling pressure, not exhaustion. The sequence 48.27 → 46.56 → 43.31 → 39.56 → 33.38 → 32.35 → 29.51 shows no relief bounces—a washout requires violent spike up after oversold.

• RSI: 29.51
• Sequence: 48.27 → 46.56 → 43.31 → 39.56 → 33.38 → 32.35 → 29.51
• No single up-day in the sequence

Bullish MACD divergence has not fired—price confirmation is required. The histogram at −1.47 confirms the bearish MACD cross is technically alive. The bear is front-running a signal that hasn't fired.

• MACD: −8.51 → −6.48 (rising while price makes lower lows)
• Histogram: −1.47 (still negative)
• Price confirmation not yet occurred

ATR compression from 10.73 to 8.30 is not capitulation—compressed ATRs precede volatility expansion that breaks support, not only mean reversion. A 1.5 ATR move down from $460 targets $447; 2 ATR targets $443.

• ATR contraction: 10.73 to 8.30
• $447: 1.5 ATR move down from $460
• $443: 2 ATR move down from $460
• Lower Bollinger Band at $464.58 being pierced without holding

The 200 SMA rising ($467.13 mid-July → $478.17 today) is a lagging echo of past strength. Price is below it for the first time meaningfully; the 50 SMA is already declining from ~$513 peak to $496.97—a rolling short-term signal that is broken.

• 200 SMA mid-July: $467.13
• 200 SMA today: $478.17
• 50 SMA peak: ~$513 (late July)
• 50 SMA current: $496.97 (already declining)
• Price below 200 SMA for first time meaningfully

If $460.20 fails on a closing basis, the next leg targets the late-2025 swing lows—a further 12–13% downside from current levels. Risk/reward is asymmetric to the downside.

• Today's low: $460.20
• Nov 3, 2025 low: $406.66
• Dec 4, 2025 low: $398.01
• Drawdown from current to Nov 2025 low: ~12%
• Drawdown from current to Dec 2025 low: ~13%

Forward estimates at cyclical inflections are most aggressive and most unreliable. The +26% growth embed in $19.56 EPS is the consensus path assuming the inflection sustains—if it doesn't, estimates get cut. Historical precedent: mid-2023 China reopening narrative consensus +15% expected, missed by ~600bps.

• Forward EPS: $19.56
• Forward EPS growth: +26%
• Q4 2025 EPS trough: $3.26
• Q1 2026 EPS: $3.98
• Q2 2026 EPS: $4.15
• Mid-2023 consensus expectation: +15%
• Mid-2023 actual outcome: missed by ~600bps

A realistic multiple for a quality industrial in a 4%+ 10Y Treasury environment is 19x—not 23x. At 19x applied to $19.56 EPS, fair value is $371. At 21x: $411. The bull's $500/$548 targets require the 23x multiple to hold, which compresses first in higher-for-longer regimes.

• 10Y Treasury: 4%+
• 19x multiple on $19.56 EPS: $371
• 21x multiple on $19.56 EPS: $411
• Bull target multiple: 23x
• Historical 2018-19 P/E: 14-16x (when growth was low-single digits)
• P/B: 5.45x (rich even by industrial standards)
• Goodwill: $27.9B
• Intangibles: $11.6B
• Total intangible assets: $39.5B
• Equity book: $39.1B

Capital return of $8.4B TTM against $5B FCF TTM is debt-funded, not FCF-funded. The $3.4B gap is financed by debt. Q2 saw $1.958B in debt issuance. This is leveraged financial engineering that becomes dangerous in higher-for-longer rates.

• Total capital return TTM: $8.4B
• FCF TTM: $5.0B
• Gap financed by debt: $3.4B
• Q2 debt issuance: $1.958B
• Net leverage: 1.7x

A defensive stock with 0.73 beta down 16% from its 52-week high is being repriced for duration risk, not showing defensive outperformance. Defensive cash flows only get relatively bid up when growth assets sell off harder. The 16% absolute drawdown empirically falsifies the theoretical defense.

• 52-week high: $548.20
• Current: $461.62
• Drawdown: ~16%
• Beta: 0.73
• Polymarket probability of zero 2026 cuts: 93%
• Every 50bps increase in discount rate compresses present value 5–7% at 23.6x forward P/E

Q2's +9.4% revenue growth is partially a price effect from 12.9% cost-of-revenue increase being passed through, not a volume effect. The +9.4% compares against a weak Q4 2025 base. The 27.3% operating margin may be the cyclical peak, not the start of expansion.

• Q2 2025 revenue growth: +1.1%
• Q3 2025 revenue growth: +0.7%
• Q4 2025 revenue growth: +2.1%
• Q1 2026 revenue growth: +3.7%
• Q2 2026 revenue growth: +9.4%
• Q2 2025 EPS: $3.73
• Q2 2026 EPS: $4.15
• Q2 2026 vs Q2 2025 EPS growth: +11.3%
• Cost of revenue increase Q2: 12.9%
• Operating margin Q2: 27.3%
• Forward estimate embeds: acceleration of acceleration